Failure of imatinib in the treatment of chronic myeloid leukemia (CML), which primarily inhibits BCR-ABL in this cancer cell line, led to the development of nilotinib as a second-line treatment, a drug that also exhibits anti-CD117 properties [142,143,144]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.